[go: up one dir, main page]

KR100522532B1 - Composition for hypoglycemic effect comprising paecilomyces japonica and momordica charantia - Google Patents

Composition for hypoglycemic effect comprising paecilomyces japonica and momordica charantia Download PDF

Info

Publication number
KR100522532B1
KR100522532B1 KR10-2003-0042835A KR20030042835A KR100522532B1 KR 100522532 B1 KR100522532 B1 KR 100522532B1 KR 20030042835 A KR20030042835 A KR 20030042835A KR 100522532 B1 KR100522532 B1 KR 100522532B1
Authority
KR
South Korea
Prior art keywords
composition
present
lowering
magnesium
blood sugar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-2003-0042835A
Other languages
Korean (ko)
Other versions
KR20050001254A (en
Inventor
윤범덕
홍종진
비탈리 유가이
조정혁
Original Assignee
주식회사 엔에스케이텍
한국과학기술연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 엔에스케이텍, 한국과학기술연구원 filed Critical 주식회사 엔에스케이텍
Priority to KR10-2003-0042835A priority Critical patent/KR100522532B1/en
Publication of KR20050001254A publication Critical patent/KR20050001254A/en
Application granted granted Critical
Publication of KR100522532B1 publication Critical patent/KR100522532B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/066—Clavicipitaceae
    • A61K36/068—Cordyceps
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

본 발명은 동충하초와 여주를 함유하는 혈당강하용 조성물에 관한 것으로, 보다 상세하게는 누에동충하초, 여주 및 마그네슘을 함유하는 혈당강하용 조성물에 관한 것이다. 본 발명에 따른 혈당강하용 조성물은 동물 실험에서 평균 60 % 이상의 혈당강하효과를 나타내었으며, 이는 각 개별성분으로는 달성할 수 없는 우수한 혈당 강하 효능이라 할 것이다. The present invention relates to a blood sugar lowering composition containing Cordyceps sinensis and Yeoju, and more particularly, to a blood glucose lowering composition containing Silkworm Cordyceps sinensis, Lime and magnesium. The hypoglycemic composition according to the present invention exhibited an average hypoglycemic effect of 60% or more in animal experiments, which would be said to be an excellent hypoglycemic effect that cannot be achieved with each individual component.

Description

동충하초와 여주를 함유하는 혈당강하용 조성물 {COMPOSITION FOR HYPOGLYCEMIC EFFECT COMPRISING PAECILOMYCES JAPONICA AND MOMORDICA CHARANTIA }Hypoglycemic composition containing Cordyceps sinensis and Yeoju {COMPOSITION FOR HYPOGLYCEMIC EFFECT COMPRISING PAECILOMYCES JAPONICA AND MOMORDICA CHARANTIA}

본 발명은 동충하초와 여주를 함유하는 혈당강하용 조성물에 관한 것으로, 보다 상세하게는 누에동충하초, 여주 및 마그네슘을 함유하는 혈당강하용 조성물에 관한 것이다. The present invention relates to a blood sugar lowering composition containing Cordyceps sinensis and Yeoju, and more particularly, to a blood glucose lowering composition containing Silkworm Cordyceps sinensis, Lime and magnesium.

당뇨병은 유전적 혹은 환경적 요인으로 인하여 발병되는 전신적인 대사질환의 일종으로서, 인슐린 의존형(제 1형)과 인슐린 비의존형(제 2형)으로 구분된다.Diabetes is a systemic metabolic disease caused by genetic or environmental factors. It is divided into insulin-dependent (type 1) and insulin-independent (type 2).

제 1형 당뇨병은 췌장의 베타(β) 세포가 선택적으로 손상 또는 파괴되어 인슐린의 양이 부족하게 되며, 심한 고혈당증과 케톤산증, 다갈, 다음, 다뇨, 체중감소 및 피로감을 나타내며, 소아에서 흔히 발생하게 된다. 제 1형 당뇨병의 치료는 인슐린의 투여로 충분하다.Type 1 diabetes is due to the selective damage or destruction of the beta (β) cells of the pancreas, resulting in a lack of insulin, severe hyperglycemia, ketoacidosis, cramping, next, polyuria, weight loss and fatigue, and are common in children. Done. Treatment of type 1 diabetes is sufficient with the administration of insulin.

이에 반해, 제 2형 당뇨병은 유전적 감수성이 높으며, 성인에 많이 발생하나 그 원인은 다양하다. 이들 원인 중 가장 많은 것은 환자들이 인슐린에 대하여 저항성을 나타낸다는 것이며, 당에 대한 인슐린의 작용부전으로 인하여 인슐린의 생산은 과다하나 과혈당 상태가 지속되는 것이 보통이다. 따라서 만성으로 경과되면 망막증, 신증, 신경장해, 동맥경화증, 감염증 및 골감소증 등의 합병증이 나타난다. 현재 제 2형 당뇨병의 치료는 식이요법과 운동요법이 일반적이고, 심한 경우에는 혈당조절을 위하여 경구 혈당강하제를 투여한다. In contrast, type 2 diabetes is genetically susceptible and occurs frequently in adults, but the causes vary. The most common of these causes is that patients are resistant to insulin. Insufficient insulin production due to insulin's insufficiency on sugar is usually caused by hyperglycemia. Therefore, when the disease is chronic, complications such as retinopathy, nephropathy, neuropathy, arteriosclerosis, infection and osteopenia appear. Currently, the treatment of type 2 diabetes is generally diet and exercise therapy, and in severe cases, oral hypoglycemic agents are administered for glycemic control.

최근에는 제 2형 당뇨병 치료를 위하여 천연추출물을 이용하여 보다 안전한 혈당강하제를 개발하려는 연구들이 진행되고 있으며, 특히 전통약물 또는 민간요법을 이용한 당뇨병의 치료법이 크게 각광을 받고 있는 추세이다. Recently, studies to develop safer blood sugar lowering agents using natural extracts for the treatment of type 2 diabetes have been progressing, and in particular, the treatment of diabetes using traditional medicine or folk remedies is in the spotlight.

이러한 추세에 따라 본 출원인은 당뇨병 치료 효과를 가지는 누에 기주의 동충하초 및 그의 재배방법에 관한 발명을 특허출원한 바 있다 (2001년 5월 14일자로 출원된 특허출원 제 2001-26194호). 기출원된 누에 기주의 동충하초는 매우 높은 활성의 우수한 당뇨병 치료 효과를 가지며, 동시에 신장 질환 등의 부작용이 매우 적다는 장점이 있다. In accordance with this trend, the present applicant has filed a patent application for Cordyceps sinensis and its cultivation method having a diabetes treatment effect (Patent Application No. 2001-26194 filed on May 14, 2001). Cordyceps sinensis of the previously applied silkworm host has a very high activity of excellent diabetes treatment, and at the same time has the advantage of very little side effects such as kidney disease.

이에, 본 발명자들은 기출원된 누에 기주의 동충하초를 그대로 포함시키면서 보다 효과적으로 혈당을 낮출 수 있는 조성물을 발명하고자 거듭 연구 노력한 결과, 누에동충하초, 여주 및 마그네슘을 함유하는 혈당강하용 조성물의 우수한 효능을 확인함으로써 본 발명을 완성하게 되었다. Thus, the present inventors have repeatedly studied to invent a composition that can effectively lower blood sugar while including the previously filed silkworm host Cordyceps, as a result, confirmed the excellent efficacy of the blood glucose lowering composition containing silkworm cordyceps, bitter gourd and magnesium Thus, the present invention has been completed.

따라서, 본 발명은 누에동충하초, 여주 및 마그네슘을 함유하는 혈당강하용 조성물을 제공하는 것이다. Accordingly, the present invention is to provide a composition for lowering blood glucose containing silkworm Cordyceps sinensis, bitter melon and magnesium.

또한, 본 발명은 상기 혈당강하용 조성물을 포함하는 건강보조식품을 제공하는 것이다. The present invention also provides a health supplement comprising the composition for lowering blood sugar.

상기한 목적을 달성하기 위하여, 본 발명에 따른 동충하초와 여주를 함유하는 조성물은 누에동충하초, 여주 및 마그네슘을 함유하는 것을 특징으로 한다. In order to achieve the above object, the composition containing Cordyceps sinensis and litchi in accordance with the present invention is characterized by containing silkworm Cordyceps sinus, litchi and magnesium.

구체적으로, 본 발명에 따른 동충하초와 여주를 함유하는 조성물은 조성물 총 중량을 기준으로, 누에동충하초 40 내지 75 중량%, 여주 20 내지 50 중량%, 수산화마그네슘 5 내지 10 중량%를 총 100 중량%가 되는 양으로 포함하여 이루어지는 것을 특징으로 한다. Specifically, the composition containing Cordyceps sinensis and Yeoju in accordance with the present invention, based on the total weight of the composition, silkworm Cordyceps sinensis 40 to 75% by weight, 20 to 50% by weight of yeast, 100% by weight of 5 to 10% by weight of magnesium hydroxide Characterized in that it comprises a quantity to be.

상기 누에동충하초는 한국특허출원 제 2001-26194호에 따른 누에동충하초인 것을 특징으로 한다. The silkworm cordyceps is characterized in that the silkworm cordyceps according to Korean Patent Application No. 2001-26194.

상기 여주는 씨를 포함하는 것을 특징으로 한다.The litter is characterized by including a seed.

상기 마그네슘은 수산화마그네슘인 것을 특징으로 한다. The magnesium is characterized in that the magnesium hydroxide.

또한 본 발명에 따른 혈당강하용 조성물은 경구투여하는 것을 특징으로 한다. In addition, the blood sugar lowering composition according to the present invention is characterized in that oral administration.

또한 본 발명에 따른 혈당강하용 조성물은 건강보조식품을 구성하는 것을 특징으로 한다. In addition, the blood sugar lowering composition according to the present invention is characterized by constituting a health supplement.

이하, 본 발명을 상세히 설명한다.  Hereinafter, the present invention will be described in detail.

본 발명에서 사용된 누에동충하초(Paecilomyces japonica Lloyd)는 본 출원인이 기출원한 한국특허출원 제 2001-26194호에 따른 누에동충하초이며, 상기 특허출원 제 2001-26194호의 내용은 그 전체가 본 발명에 참고된다.The silkworm cordyceps used in the present invention (Paecilomyces japonica Lloyd) is a silkworm cordyceps according to Korean Patent Application No. 2001-26194 filed by the present applicant, the contents of the patent application 2001-26194 is referred to in the present invention in its entirety do.

본 발명에서 사용된 여주(Momordica charantia L)는 쌍떡잎식물 박목 박과의 덩굴성 한해살이풀인 관상식물로서, 잎은 손바닥 모양으로 갈라져 있고 여름과 가을에 노란 꽃이 피며, 길고 둥근 열매에는 혹 같은 것이 우툴두툴 돋아 있는 것이 특징이다 (도 2 참조). 주로 남아메리카, 인도, 동남아, 아프리카 등의 열대지방에서 자생 또는 재배되며, 차, 분말, 음식의 요리재료 등 다양한 방법으로 활용되고 있다. 특히 자생하는 지역이 있어 국내에서는 아직 적극적으로 활용되지 않고 있으나, 중국 및 서구에서는 요리의 활용과 더불어 민간요법으로서 다이어트와 면역기능강화 등에 활용되고 있다.Yeoju (Momordica charantia L) used in the present invention is a vine of perennial herbaceous perennial herbaceous plants, leaves are divided into palm-shaped, yellow flowers in summer and autumn, humps on long, round berries It is characterized by sprouting u-tool du thu (see FIG. 2). It is grown or cultivated mainly in tropical regions such as South America, India, Southeast Asia, and Africa, and is used in various ways such as tea, powder, and food ingredients. In particular, because it is a native area, it is not actively used in Korea, but in China and the West, it is used for diet and strengthening of immune function as a folk remedy as well as cooking.

본 발명에서 사용된 마그네슘(Mg)은 인체의 기능에 있어서 특히 전해질과 효소활성기능을 갖는데 필수적인 미네랄로서, 칼슘(Ca), 인(P)과 매우 밀접한 관계가 있으며, 세포내의 비생리학적 칼슘의 배출과 생리학적 칼슘의 흡수에 매우 중요한 역할을 한다. 또한 다른 미네랄들의 대사 작용에도 중요한 역할을 하며. 세포 내에 존재하면서 에너지 생산을 조절하는 효소계의 70 %에 관계하며 ATP를 ADP로 전환시키는 에너지 전환작용에 절대적으로 필요하다. 특히 혈관확장, 근육경련방지, 면역기능강화작용 등과 더불어 당 대사에도 중요한 작용을 한다. 본 발명에서는 동충하초성분과 여주성분의 작용 촉진을 위한 촉매 역할을 한다. Magnesium (Mg) used in the present invention is an essential mineral for having electrolyte and enzymatic activity, especially in the function of the human body, and is closely related to calcium (Ca) and phosphorus (P). It plays a very important role in the release and absorption of physiological calcium. It also plays an important role in the metabolism of other minerals. It is present in the cell and accounts for 70% of the enzyme system that regulates energy production and is absolutely necessary for energy conversion to convert ATP to ADP. In particular, in addition to vascular expansion, muscle spasms, immune function, and also plays an important role in sugar metabolism. In the present invention, it serves as a catalyst for promoting the action of Cordyceps sinensis and gourds.

본 발명에 따른 혈당강하용 조성물을 구성하는 누에동충하초와 여주는 각각 증류수와 혼합하여 가열한 다음, 여과 후 동결건조시켜 분말화하여 사용할 수 있다. 이 때, 여주의 씨를 제거하지 않고 함께 분말화하여 사용하는 것이 혈당강하효과가 더욱 뛰어나다. 또한 마그네슘으로는 수산화마그네슘 (Mg(OH)2)을 사용할 수 있다.Silkworm Cordyceps and Yeoju constituting the blood sugar lowering composition according to the present invention can be mixed with distilled water and heated, and then lyophilized after filtration to be powdered. At this time, it is more effective to lower the blood sugar by using the powder together without removing the seeds of the yeast. In addition, magnesium hydroxide (Mg (OH) 2 ) may be used as magnesium.

본 발명에 따른 혈당강하용 조성물의 제형은 액상, 분말, 과립 형태 등 용도에 따라 다양한 제형으로 제조할 수 있다. 또한 본 발명에 따른 혈당강하용 조성물은 경구투여하여 사용할수 있다.The formulation of the blood glucose lowering composition according to the present invention can be prepared in various formulations according to the use, such as liquid, powder, granule form. In addition, the composition for lowering blood sugar according to the present invention can be used by oral administration.

이하 실시예를 들어 본 발명을 더욱 상세히 설명할 것이나, 이들 실시예는 어디까지나 본 발명의 이해를 돕기 위해 제시되는 예시적 구체예에 불과할 뿐, 본 발명의 보호범위가 이들 실시예로 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following examples, but these examples are merely exemplary embodiments presented to aid the understanding of the present invention, and the protection scope of the present invention is limited to these examples. no.

실시예 1Example 1

혈당강하용 조성물의 준비Preparation of hypoglycemic composition

본 출원인이 기출원한 특허출원 제 2001-26194호에 따른 누에동충하초 30 g을 300 ml 증류수에 주입하여, 약 80 ℃에서 4 시간 동안 가열한 다음, 여과시켜 - 50 ℃에서 동결건조시켜 분말로 준비하였다. 30 g of Silkworm Cordyceps sinensis according to the patent application No. 2001-26194 filed by the applicant to 300 ml distilled water, heated at about 80 ℃ for 4 hours, filtered and freeze-dried at 50 ℃ to prepare a powder It was.

여주는 씨를 제거하지 않는 채 증류수와 50 : 50의 비율로 혼합하여 100 ℃에서 45 분 동안 가열하여, 23 ℃에서 36 시간 동안 보관한 후, 여과시켜 - 50 ℃에서 동결건조시켜 분말로 준비하였다.The litchi was mixed with distilled water at a ratio of 50:50 without removing the seed, heated at 100 ° C. for 45 minutes, stored at 23 ° C. for 36 hours, and then filtered and lyophilized at −50 ° C. to prepare a powder.

혈당강하용 조성물의 촉매성분으로서 수산화마그네슘 (Mg(OH)2)을 준비하였다.Magnesium hydroxide (Mg (OH) 2 ) was prepared as a catalyst component of the blood glucose lowering composition.

실시예 2Example 2

혈당강하용 조성물의 제조Preparation of hypoglycemic composition

(1) 혈당강하용 조성물의 각 구성성분 단독의 혈당강하효과(1) hypoglycemic effect of each component of the blood glucose lowering composition alone

본 발명에 따른 혈당강하용 조성물의 제조에 앞서, 각 구성성분인 누에동충하초, 여주추출물, 및 수산화마그네슘 각각의 혈당강하효과를 측정해 보기 위하여, 35 g 전후의 당뇨유도쥐(diabetic mouse)의 수컷 10 마리를 구입하여 3 주간 섭씨 21 ℃, 습도 65 %의 실험동물사육실에서 사료와 물을 충분히 공급하면서, 실험 환경에 적응시켜 실험에 사용하였고, 각 당뇨유도쥐의 눈에서 파스테르파이펫로 150~200 ppm의 혈액을 채취하여 혈당을 측정하였다. Prior to the preparation of the hypoglycemic composition according to the present invention, in order to measure the hypoglycemic effect of each component of silkworm Cordyceps sinensis, bitumen extract, and magnesium hydroxide, males of diabetic mouse around 35 g 10 animals were purchased for 3 weeks at 21 ℃ and 65% humidity in the experimental animal feeding room with sufficient feed and water, and adapted to the experimental environment was used in the experiment, each of the diabetic induction rats with a paste pipette 150 Blood glucose was measured by taking blood of ˜200 ppm.

누에동충하초, 여주추출물 및 수산화마그네슘을 각각 단독으로 1 일 1 회 3 mg씩 3 주간 당뇨유도쥐에 경구투여한 다음, 혈당을 측정한 결과, 누에동충하초, 여주추출물 그리고 수산화마그네슘 각각으로부터 약 42 %, 약 27.7%, 그리고 약 26.36 %의 혈당강하효과를 확인할 수 있었다.Silkworm cordyceps, yeast extract and magnesium hydroxide were administered orally to the diabetic induction rats for 3 weeks, 3 mg once daily, and then blood glucose was measured. About 42% of silkworm cordyceps, yeast extract and magnesium hydroxide, respectively, About 27.7% and about 26.36% of the blood sugar lowering effect was confirmed.

(2) 혈당강하용 조성물의 최적 배합비(2) Optimal compounding ratio of blood sugar lowering composition

본 발명에 따른 혈당강하용 조성물의 최적 배합비를 알아보기 위하여, 기본적으로 성인 체중 60 kg을 기준으로 하여 실험대상인 당뇨유도쥐의 체중 35 g 대비 1회 투여량을 계산하여 혈당강하용 조성물의 배합비율을 다양하게 바꾸어 가며, 상기 (1)과 동일한 방법으로 혈당강하효과를 측정하였다. 그 결과를 하기 표 1 및 표 2에 나타내었다. In order to find out the optimal compounding ratio of the blood sugar lowering composition according to the present invention, the compounding ratio of the blood sugar lowering composition was calculated by calculating a one-dose compared to the weight of 35 g of the diabetic induction mouse subject based on 60 kg adult weight By varying the various, blood glucose lowering effect was measured in the same manner as in (1). The results are shown in Tables 1 and 2 below.

(10 % 수산화마그네슘 기준)(Based on 10% magnesium hydroxide) 조성물 배합비율 (%)Composition ratio (%) 혈당강하효과 (%)Hypoglycemic effect (%) 누에동충하초Silkworm Cordyceps 여주추출물Yeoju extract 수산화마그네슘Magnesium hydroxide 00 100100 00 25.9925.99 00 9090 1010 30.5730.57 1010 8080 1010 33.4133.41 2020 7070 1010 39.7139.71 3030 6060 1010 44.8544.85 4040 5050 1010 54.4654.46 5050 4040 1010 60.0560.05 6060 3030 1010 60.0760.07 7070 2020 1010 50.6250.62 8080 1010 1010 43.3143.31 9090 00 1010 40.8840.88 100100 00 00 39.7739.77

(5 % 수산화마그네슘)(5% Magnesium Hydroxide) 조성물 배합비율 (%)Composition ratio (%) 혈당강하효과 (%)Hypoglycemic effect (%) 누에동충하초Silkworm Cordyceps 여주추출물Yeoju extract 수산화마그네슘Magnesium hydroxide 00 100100 00 24.5924.59 55 9090 55 29.5529.55 1515 8080 55 31.7731.77 2525 7070 55 38.5638.56 3535 6060 55 41.5841.58 4545 5050 55 53.6453.64 5555 4040 55 59.8859.88 6565 3030 55 60.2460.24 7575 2020 55 55.1155.11 8585 1010 55 46.2246.22 9595 00 55 40.9840.98 100100 00 00 40.2140.21

상기 표 1 및 표 2에 따라, 본 발명에 따른 혈당강하용 조성물의 최적 배합비는 누에동충하초 46.875 중량%, 여주 46.875 중량%, 그리고 수산화마그네슘 6.25 중량%가 바람직하다. According to Table 1 and Table 2, the optimal blending ratio of the blood sugar lowering composition according to the present invention is 46.875% by weight silkworm Cordyceps, 46.875% by weight Yeoju, and 6.25% by weight of magnesium hydroxide.

실시예 3Example 3

혈당강하용 조성물의 혈당강하효과 확인Confirmation of hypoglycemic effect of hypoglycemic composition

상기 실시예 2에서 얻어진 본 발명에 따른 혈당강하용 조성물의 최적 배합비에 따라, 마우스의 체중 35 g 대비 누에동충하초 3 mg, 여주 3 mg, 및 수산화마그네슘 0.4 mg으로 이루어진 본 발명에 따른 혈당강하용 조성물 6.4 mg을 1 일 1 회씩 3 주간 당뇨유도쥐에게 경구투여한 결과, 평균 60.18%의 우수한 혈당강하효과를 확인하였다. 그 결과를 표 3에 나타내었다. According to the optimal compounding ratio of the blood sugar lowering composition according to the present invention obtained in Example 2, the composition for lowering blood sugar according to the present invention consisting of 3 mg of silkworm cordyceps, 3 mg of bitter gourd, and 0.4 mg of magnesium hydroxide compared to 35 g of body weight of the mouse As a result of oral administration of 6.4 mg to diabetic induction rats once a day for 3 weeks, an average blood glucose lowering effect of 60.18% was confirmed. The results are shown in Table 3.

혈당수치 (mg/dl)Blood glucose level (mg / dl) 체중 (g)Body weight (g) 혈당강하효과(%)Hypoglycemic effect (%) 1 주1 week 4 주4 weeks 1 주1 week 4 주4 weeks 167167 7171 32.032.0 34.534.5 57.4957.49 142142 5454 34.534.5 36.536.5 61.9761.97 155155 6868 31.531.5 31.031.0 56.1356.13 145145 5757 32.032.0 33.033.0 60.6960.69 147147 5252 32.032.0 32.532.5 64.6364.63

이상과 같이, 본 발명에 따른 혈당강하용 조성물은 동물실험에서 평균 60 % 이상의 혈당강하효과를 나타내었으며, 이는 각 개별성분으로는 달성할 수 없는 우수한 혈당 강하 효능이 아닐 수 없다.As described above, the blood glucose lowering composition according to the present invention exhibited an average blood glucose lowering effect of 60% or more in animal experiments, which is an excellent blood sugar lowering effect that cannot be achieved with each individual component.

따라서 본 발명에 따른 혈당강하용 조성물을 이용함으로써 당뇨병으로 인한 고혈당관리에 효율적으로 활용될 수 있으며, 각종 물리 화학적 방법을 통하여 약효성분을 추출함으로서 약용물질의 대량생산이 가능할 것으로 기대된다. 이는 현재 경구혈당강하제 및 인슐린요법에 의존하고 있는 당뇨병 치료에서 벗어나 식품에서 의약품의 개발에 이르기까지 다양한 활용이 가능할 것으로 기대된다. Therefore, by using the blood sugar lowering composition according to the present invention can be effectively used for hyperglycemia management due to diabetes, it is expected that the mass production of medicinal substances by extracting the active ingredient through various physicochemical methods. This is expected to be able to use a variety of applications ranging from food to the development of drugs from diabetes treatment, which currently depends on oral hypoglycemic agents and insulin therapy.

도 1은 5령 3일 누에를 기주로 한 동충하초(Paecilomyces japonica Lloyd)의 사진이다.1 is a photograph of the Cordyceps sinensis (Paecilomyces japonica Lloyd) based on the silkworm 5 days 3 days.

도 2는 여주(Momordica charantia L)의 사진이다.2 is a photograph of the bitumen (Momordica charantia L).

Claims (7)

누에동충하초, 여주 및 마그네슘을 함유하는 혈당강하용 조성물.Silkworm cordyceps, yeast and magnesium containing blood glucose lowering composition. 제 1항에 있어서, 조성물 총 중량을 기준으로, 누에동충하초 40 내지 75 중량%, 여주 20 내지 50 중량%, 및 마그네슘 5 내지 10 중량%를 총 100 중량%가 되는 양으로 포함하여 이루어진 혈당강하용 조성물.The method for lowering blood sugar of claim 1, comprising 40 to 75% by weight of silkworm cordyceps, 20 to 50% by weight, and 5 to 10% by weight of magnesium, based on the total weight of the composition. Composition. 제 1항 또는 제 2항에 있어서, 상기 누에동충하초가 한국특허출원 제 2001-26194호에 따른 누에동충하초인 것을 특징으로 하는 혈당강하용 조성물.The blood glucose lowering composition according to claim 1 or 2, wherein the silkworm cordyceps is a silkworm cordyceps according to Korean Patent Application No. 2001-26194. 제 1항 또는 제 2항에 있어서, 상기 여주가 씨를 포함하는 것을 특징으로 하는 혈당강하용 조성물.The blood sugar lowering composition according to claim 1 or 2, wherein the bitter gourd comprises seeds. 제 1항 또는 제 2항에 있어서, 상기 마그네슘이 수산화마그네슘인 것을 특징으로 하는 혈당강하용 조성물.The hypoglycemic composition according to claim 1 or 2, wherein the magnesium is magnesium hydroxide. 제 1항 또는 제 2항에 있어서, 경구투여하는 것을 특징으로 하는 혈당강하용 조성물.The composition for lowering blood glucose according to claim 1 or 2, which is orally administered. 삭제delete
KR10-2003-0042835A 2003-06-27 2003-06-27 Composition for hypoglycemic effect comprising paecilomyces japonica and momordica charantia Expired - Fee Related KR100522532B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR10-2003-0042835A KR100522532B1 (en) 2003-06-27 2003-06-27 Composition for hypoglycemic effect comprising paecilomyces japonica and momordica charantia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-2003-0042835A KR100522532B1 (en) 2003-06-27 2003-06-27 Composition for hypoglycemic effect comprising paecilomyces japonica and momordica charantia

Publications (2)

Publication Number Publication Date
KR20050001254A KR20050001254A (en) 2005-01-06
KR100522532B1 true KR100522532B1 (en) 2005-10-20

Family

ID=37217081

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-0042835A Expired - Fee Related KR100522532B1 (en) 2003-06-27 2003-06-27 Composition for hypoglycemic effect comprising paecilomyces japonica and momordica charantia

Country Status (1)

Country Link
KR (1) KR100522532B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100952188B1 (en) 2008-05-19 2010-04-09 이수명 Dietary supplement for glycated hemoglobin

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100675311B1 (en) * 2005-07-12 2007-01-30 강원생물영농조합법인 Manufacturing method of health functional food for lowering blood sugar
KR101118451B1 (en) * 2009-10-26 2012-03-09 심재학 Composition comprising extracts of Radix Smilax china, Paecilomyces japonica and Momordica charantia for hypoglycemic agent]

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100952188B1 (en) 2008-05-19 2010-04-09 이수명 Dietary supplement for glycated hemoglobin

Also Published As

Publication number Publication date
KR20050001254A (en) 2005-01-06

Similar Documents

Publication Publication Date Title
Kumar et al. Recent trends in potential traditional Indian herbs Emblica officinalis and its medicinal importance
CN101023967B (en) Compound extract of common phellinus fungus and chaga, its preparing method and preparation
CN1143681C (en) Medicinal composition for diabetes
CN101116497A (en) Composite propolis capsule health-care food
KR101118451B1 (en) Composition comprising extracts of Radix Smilax china, Paecilomyces japonica and Momordica charantia for hypoglycemic agent]
Sumon et al. Comparative efficacy of powdered form of Stevia (Stevia rebaudiana Bertoni) leaves and glimepiride in induced diabetic rats
KR100522532B1 (en) Composition for hypoglycemic effect comprising paecilomyces japonica and momordica charantia
CN1907374A (en) Chinese medicinal composition for treating oral disease
CN111803559B (en) A kind of eggplant peel composition with hypoglycemic effect and preparation method and application thereof
CN101491605A (en) Combination with blood sugar reducing function and preparation method thereof
KR100959281B1 (en) Calcium compound fertilized rice of hypoglycemic effect
KR101660232B1 (en) Hypoglycemic agent with a natural plant and manufacturing method
CN104288527B (en) It is a kind of to be used to treat Chinese medicine composition of diabetes and preparation method and application
CN108260682A (en) A kind of hypoglycemic, reducing blood lipid and the health protection tea of blood pressure lowering
CN110063977B (en) Radix codonopsis and sea buckthorn composite electuary and application thereof
KR20100072709A (en) Composition for preventing and treating diabetics by hyperglycemic action
WO2006030426A1 (en) Herbal compositions for treatment of diabetes
CN105613736A (en) Composite probiotic beverage prepared by utilizing pawpaw extract
US20050175716A1 (en) Method and herbal composition for treatment of diabetes
KR100894029B1 (en) Pharmaceutical composition for the prevention of diabetes from the ginseng flower and pharmaceutical composition for the treatment
CN110876717A (en) Preparation method of product capable of stabilizing blood sugar
RU2224536C1 (en) Medicinal agent for treatment of pancreatitis and diabetes mellitus
KR20030079289A (en) The carbonated soft drinks a manufacturing process and a composition of ling indigestion hangover cures.
CN103751255A (en) Pachymaran composition for decreasing blood sugar and preparation method thereof
CN101274000B (en) Medicine use of herb aralia elata seem

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20091013

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

K11-X000 Ip right revival requested

St.27 status event code: A-6-4-K10-K11-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20091013

PR0401 Registration of restoration

St.27 status event code: A-6-4-K10-K13-oth-PR0401

R401 Registration of restoration
PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20101013

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

K11-X000 Ip right revival requested

St.27 status event code: A-6-4-K10-K11-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20101013

PR0401 Registration of restoration

St.27 status event code: A-6-4-K10-K13-oth-PR0401

R401 Registration of restoration
PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20111013

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

FPAY Annual fee payment

Payment date: 20120713

Year of fee payment: 7

K11-X000 Ip right revival requested

St.27 status event code: A-6-4-K10-K11-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20111013

PR0401 Registration of restoration

St.27 status event code: A-6-4-K10-K13-oth-PR0401

R401 Registration of restoration
PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20121013

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20121013

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301